文献速递肺结节与肺癌肺栓塞与肺血管病

低分子肝素在局限性肺癌中的抗肿瘤作用:一项III期临床试验

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
PubMed 文献 · Eur Respir J · 2018-10-04

这项开放标签、盲法中心判定的III期试验将549例完全切除的I-IIIA期非小细胞肺癌患者随机分配接受皮下替扎肝素100 IU·kg-1每日一次共12周或不治疗。中位随访5.7年,两组总生存无显著差异(HR 1.24,95%CI 0.92-1.68;p=0.17),复发累积发生率也无差异(亚分布HR 0.94,95%CI 0.68-1.30;p=0.70)。

要点

  • 辅助替扎肝素未改善完全切除I-IIIA期NSCLC的总生存。
  • 替扎肝素对复发累积发生率无显著影响。
  • 结果不支持将低分子肝素作为抗肿瘤药物进一步临床评价。

核心结论

  • 辅助替扎肝素对完全切除的I-IIIA期NSCLC患者的总生存和复发-free生存均无可检测的影响。

研究设计与样本

  • 完全切除的I、II或IIIA期NSCLC患者随机接受皮下替扎肝素100 IU·kg-1每日一次共12周或不治疗,外加标准治疗。
  • 试验为开放标签设计,研究结局采用盲法中心判定。
  • 共549例患者随机分配至替扎肝素组(n=269)或对照组(n=280)。
  • 主要结局为总生存。

主要发现

  • 替扎肝素组与对照组的总生存无显著差异(HR 1.24,95%CI 0.92-1.68;p=0.17)。
  • 两组复发累积发生率无差异(亚分布HR 0.94,95%CI 0.68-1.30;p=0.70)。
  • 患者平均±标准差年龄为61.6±8.9岁,190例(34.6%)为II-III期疾病,220例(40.1%)接受辅助化疗。
  • 中位随访时间为5.7年。

临床怎么用

  • 对于完全切除的I-IIIA期NSCLC患者,不应出于抗肿瘤目的使用低分子肝素替扎肝素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg-1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269) or control (n=280), mean±sd age was 61.6±8.9 years, 190 (34.6%) patients had stage II-III disease, and 220 (40.1%) patients received adjuvant chemotherapy. Median follow-up was 5.7 years. There was no significant difference in overall survival between groups (hazard ratio (HR) 1.24, 95% CI 0.92-1.68; p=0.17). There was no difference in the cumulative incidence of recurrence between groups (subdistribution HR 0.94, 95% CI 0.68-1.30; p=0.70).Adjuvant tinzaparin had no detectable impact on overall and recurrence-free survival of patients with completely resected stage I-IIIA NSCLC. These results do not support further clinical evaluation of LMWHs as anti-tumour agents.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Meyer G, Besse B, Doubre H, et al. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018. PMID: 30262574. doi:10.1183/13993003.01220-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。